Report Scope:
The report will provide details about autoimmune disorder therapies used in the treatment of autoimmune disease and how it has been influenced by the pandemic of COVID-19. This report will also highlight the current and future market potentiality of autoimmune disorder therapies with detailed analyses of the competitive environments between companies. Drivers, restraints, opportunities, pricing analysis, prevalence or incidence autoimmune disease, and regulatory scenarios will also be covered. The report includes a market projection for 2024 and market shares for key players.
The report segments the market for autoimmune therapies based on drug class, indications, and geography. Based on drug class, the market is segmented into immunosuppressants and NSAIDs. The immunosuppressant drug class is further segmented into corticosteroids, biologics, and inhibitors. The market size includes drug class and its major brands on sale and serviceable in the market. Based on indications, the market is segmented into type 1 diabetes, rheumatoid arthritis (RA), psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus (SLE), and others (pernicious anemia, celiac disease, autoimmune vasculitis, myasthenia gravis, Hashimoto’s thyroiditis, Sjögren’s syndrome, Graves’ disease, Addison’s disease, etc.).
By geography, the market has been segmented into North America, Europe, the Asia-Pacific, and the Rest of the World. A detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, Gulf Cooperation Council countries, and South Africa will be covered in the regional segments. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast values for 2024.
Report Includes:
- 30 data tables and 18 additional tables
- An overview of the global markets for autoimmune disorder therapies
- Estimation of the market size and analyses of market trends, with data from 2018, 2019 and projection of CAGR through 2024
- Characterization and quantification of autoimmune disorder therapies based on drug class, age group, and region
- Impact analysis of COVID-19 pandemic on autoimmune disorder therapies market and highlights of the current and future market potential of these therapies
- Evaluation of current market trends, market size, market forecast, and detailed analysis of drivers, challenges, and opportunities affecting the market growth
- Market share analysis of the key companies of the industry, their strategic profiling, their competitive landscape, and their detailed company profiles, including AstraZeneca, Vertex Pharmaceuticals Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Roche), Pfizer Inc., and Johnson and Johnson
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Autoimmune Disorder Therapies
- Biologics as Autoimmune Disorder Therapies
- Trends in Autoimmune Disorder Therapies
Chapter 4 Market Dynamics
- Market Drivers
- Increasing Epidemiology of Autoimmune Diseases
- The rise in the Geriatric Population
- Rising Awareness of Autoimmune Diseases
- New Therapeutic Pathway for Autoimmune and Inflammatory Disorders
- Market Restraints
- Side Effects of Therapeutics
- High Cost of Autoimmune Disorder Therapies
- Market Opportunities
- Launch of New Therapeutics for Autoimmune Diseases
- Growing use of Autoimmune Disorder Therapies for COVID-19 Patients
Chapter 5 Market Breakdown by Drug Class
- Global Market for Autoimmune Disorder Therapies
- NSAIDs
- Market Size and Forecast
- Market Analysis
- Immunosuppressant Drugs
- Market Size and Forecast
- Market Analysis
- Corticosteroids
- Biologics
- Inhibitors
Chapter 6 Market Breakdown by Indication
- Global Market for Autoimmune Disorder Therapies by Indication
- Type 1 Diabetes
- Market Size and Forecast
- Rheumatoid Arthritis
- Market Size and Forecast
- Psoriasis/Psoriatic Arthritis
- Market Size and Forecast
- Multiple Sclerosis
- Market Size and Forecast
- Inflammatory Bowel Disease
- Market Size and Forecast
- Systemic Lupus Erythematosus
- Market Size and Forecast
- Other Autoimmune Diseases
- Market Size and Forecast
Chapter 7 Market Breakdown by Region
- Global Market for Autoimmune Disorder Therapies by Region
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia and New Zealand
- Rest of Asia-Pacific
- Rest of World
- Market Analysis
- Brazil
- Gulf Cooperation Council Countries
- South Africa
- Remaining Rest of World Countries
Chapter 8 Impact of COVID-19
Chapter 9 Therapeutics Pipeline
Chapter 10 Competitive Landscape
- Global Company Share Analysis
- Mergers and Acquisitions
- Agreements, Launches, Collaborations, and Partnerships
Chapter 11 Company Profiles
- Abbvie Inc.
- Amgen Inc.
- Astrazeneca
- Bayer Ag
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Mylan N.V.
- Novartis Ag
- Pfizer Inc.
- Vertex Pharmaceuticals Inc.
Chapter 12 Appendix: Acronyms
List of Tables
Summary Table B: Global Market for Autoimmune Disorder Therapies, by Indication, Through 2024
Summary Table A: Global Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
Table 1: Biologics as Autoimmune Disorder Therapies
Table 2: Effect of Some Autoimmune Disease Drugs on the Clinical Course of Patients with COVID-19
Table 3: Global Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
Table 4: Global Market for NSAIDs for Autoimmune Disorder Therapies, by Region, Through 2024
Table 5: Global Market for Immunosuppressant Drugs for Autoimmune Disorder Therapies, by Region, Through 2024
Table 6: Therapeutic Effects of Glucocorticoids
Table 7: Global Market for Corticosteroids for Autoimmune Disorder Therapies, by Region, Through 2024
Table 8: Global Market for Biologics for Autoimmune Disorder Therapies, by Region, Through 2024
Table 9: Global Market for Inhibitors for Autoimmune Disorder Therapies, by Region, Through 2024
Table 10: Global Market for Autoimmune Disorder Therapies, by Indication, Through 2024
Table 11: Global Market for Autoimmune Disorder Therapies for Type 1 Diabetes, by Region, Through 2024
Table 12: Global Market for Autoimmune Disorder Therapies for Rheumatoid Arthritis, by Region, Through 2024
Table 13: Global Market for Autoimmune Disorder Therapies for Psoriasis/Psoriatic Arthritis, by Region, Through 2024
Table 14: Drugs in the Pipeline for Psoriatic Disease
Table 15: Global Market for Autoimmune Disorder Therapies for Multiple Sclerosis, by Region, Through 2024
Table 16: Global Market for Autoimmune Disorder Therapies for Inflammatory Bowel Disease, by Region, Through 2024
Table 17: Global Market for Autoimmune Disorder Therapies for Systemic Lupus Erythematosus, by Region, Through 2024
Table 18: Global Market for Autoimmune Disorder Therapies for Other Autoimmune Diseases, by Region, Through 2024
Table 19: Global Market for Autoimmune Disorder Therapies, by Region, Through 2024
Table 20: North American Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
Table 21: North American Market for Autoimmune Disorder Therapies, by Indication, Through 2024
Table 22: North American Market for Autoimmune Disorder Therapies, by Country, Through 2024
Table 23: European Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
Table 24: European Market for Autoimmune Disorder Therapies, by Indication, Through 2024
Table 25: European Market for Autoimmune Disorder Therapies, by Country, Through 2024
Table 26: Asia-Pacific Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
Table 27: Asia-Pacific Market for Autoimmune Disorder Therapies, by Indication, Through 2024
Table 28: Asia-Pacific Market for Autoimmune Disorder Therapies, by Country, Through 2024
Table 29: Rest of World Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
Table 30: Rest of World Market for Autoimmune Disorder Therapies, by Indication, Through 2024
Table 31: Rest of World Market for Autoimmune Disorder Therapies, by Country/Region, Through 2024
Table 32: Pharmaceutical Companies Involved in COVID-19 Testing and Research
Table 33: Anti-TNF Biosimilars and Others in the Development for the Treatment of Autoimmune Inflammatory Diseases
Table 34: AbbVie Inc.: Product Portfolio
Table 35: Amgen Inc.: Product Portfolio
Table 36: AstraZeneca: Product Portfolio
Table 37: Bayer AG: Product Portfolio
Table 38: Bristol-Myers Squibb: Product Portfolio
Table 39: F. Hoffmann-La Roche & Co.: Antibiotics Product Portfolio
Table 40: Johnson & Johnson: Product Portfolio
Table 41: Mylan N.V.: Product Portfolio
Table 42: Novartis AG: Product Portfolio
Table 43: Pfizer Inc.: Product Portfolio
Table 44: Pfizer Inc.: Pipeline Product Portfolio
Table 45: Vertex Pharmaceuticals Inc.: Antibiotics Product Portfolio
Table 46: Acronyms Used in This Report
List of Figures
Summary Figure A: Global Market for Autoimmune Disorder Therapies, by Drug Class, 2018-2024
Summary Figure B: Global Market Share of Autoimmune Disorder Therapies, by Indication, 2019
Figure 1: Prevalence of Diagnosed Autoimmune Conditions in Selected Countries, 2019
Figure 2: Deaths Due to Diabetes in Adults, by Age Group and Sex, 2019
Figure 3: Number of Diabetes Patients (Ages 20-79 years), Projection and Trends, 2000-2045
Figure 4: Global Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
Figure 5: Global Market Share of Autoimmune Disorder Therapies, by Immunosuppressant Drug, 2019
Figure 6: Global Market for NSAIDs for Autoimmune Disorder Therapies, 2018-2024
Figure 7: Global Market for NSAIDs for Autoimmune Disorder Therapies, by Region, 2018-2024
Figure 8: Global Market for Autoimmune Disorder Therapies, by Immunosuppressant Drug, 2018-2024
Figure 9: Global Market Share of Autoimmune Disorder Therapies, by Immunosuppressant Drug, 2019
Figure 10: Global Market for Immunosuppressant Drugs for Autoimmune Disorder Therapies, by Region, 2018-2024
Figure 11: Global Market for Corticosteroids for Autoimmune Disorder Therapies, 2018-2024
Figure 12: Global Market for Corticosteroids for Autoimmune Disorder Therapies, by Region, 2018-2024
Figure 13: Global Market for Biologics for Autoimmune Disorder Therapies, 2018-2024
Figure 14: Global Market for Biologics for Autoimmune Disorder Therapies, by Region, 2018-2024
Figure 15: Global Market for Inhibitors for Autoimmune Disorder Therapies, 2018-2024
Figure 16: Global Market for Inhibitors for Autoimmune Disorder Therapies, by Region, 2018-2024
Figure 17: Global Market Share of Autoimmune Disorder Therapies, by Indication, 2019
Figure 18: Global Prevalence of Major Autoimmune Diseases, 2016 and 2017 Per 100,000
Figure 19: Global Market for Autoimmune Disorder Therapies for Type 1 Diabetes, 2018-2024
Figure 20: Global Market for Autoimmune Disorder Therapies for Type 1 Diabetes, by Region, 2018-2024
Figure 21: Global Market for Autoimmune Disorder Therapies for Rheumatoid Arthritis, 2018-2024
Figure 22: Global Market for Autoimmune Disorder Therapies for Rheumatoid Arthritis, by Region, 2018-2024
Figure 23: Global Market for Autoimmune Disorder Therapies for Psoriasis/Psoriatic Arthritis, 2018-2024
Figure 24: Global Market for Autoimmune Disorder Therapies for Psoriasis/Psoriatic Arthritis, by Region, 2018-2024
Figure 25: Global Market for Autoimmune Disorder Therapies for Multiple Sclerosis, 2018-2024
Figure 26: Global Market for Autoimmune Disorder Therapies for Multiple Sclerosis, by Region, 2018-2024
Figure 27: Global Market for Autoimmune Disorder Therapies for Inflammatory Bowel Disease, 2018-2024
Figure 28: Global Market for Autoimmune Disorder Therapies for Inflammatory Bowel Disease, by Region, 2018-2024
Figure 29: Global Market for Autoimmune Disorder Therapies for Systemic Lupus Erythematosus, 2018-2024
Figure 30: Global Market for Autoimmune Disorder Therapies for Systemic Lupus Erythematosus, by Region, 2018-2024
Figure 31: Global Market for Autoimmune Disorder Therapies for Other Autoimmune Diseases, 2018-2024
Figure 32: Global Market for Autoimmune Disorder Therapies for Other Autoimmune Diseases, by Region, 2018-2024
Figure 33: Global Market Share of Autoimmune Disorder Therapies, by Region, 2019
Figure 34: North American Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
Figure 35: North American Market Share of Autoimmune Disorder Therapies, by Immunosuppressant Drugs, 2019
Figure 36: North American Market Share of Autoimmune Disorder Therapies, by Indication, 2019
Figure 37: North American Market Share of Autoimmune Disorder Therapies, by Country, 2019
Figure 38: U.S. Market for Autoimmune Disorder Therapies, 2018-2024
Figure 39: Canadian Market for Autoimmune Disorder Therapies, 2018-2024
Figure 40: Mexican Market for Autoimmune Disorder Therapies, 2018-2024
Figure 41: European Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
Figure 42: European Market Share of Autoimmune Disorder Therapies, by Type of Immunosuppressant Drug, 2019
Figure 43: European Market Share of Autoimmune Disorder Therapies, by Indication, 2019
Figure 44: European Market Share of Autoimmune Disorder Therapies, by Country, 2019
Figure 45: German Market for Autoimmune Disorder Therapies, 2018-2024
Figure 46: French Market for Autoimmune Disorder Therapies, 2018-2024
Figure 47: U.K. Market for Autoimmune Disorder Therapies, 2018-2024
Figure 48: Italian Market for Autoimmune Disorder Therapies, 2018-2024
Figure 49: Spanish Market for Autoimmune Disorder Therapies, 2018-2024
Figure 50: Rest of Europe Market for Autoimmune Disorder Therapies, 2018-2024
Figure 51: Asia-Pacific Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
Figure 52: Asia-Pacific Market Share of Autoimmune Disorder Therapies, by Type of Immunosuppressant Drug, 2019
Figure 53: Asia-Pacific Market Share of Autoimmune Disorder Therapies, by Indication, 2019
Figure 54: Asia-Pacific Market Share of Autoimmune Disorder Therapies, by Country, 2019
Figure 55: Japanese Market for Autoimmune Disorder Therapies, 2018-2024
Figure 56: Chinese Market for Autoimmune Disorder Therapies, 2018-2024
Figure 57: Indian Market for Autoimmune Disorder Therapies, 2018-2024
Figure 58: Australian and New Zealand Market for Autoimmune Disorder Therapies, 2018-2024
Figure 59: Rest of Asia-Pacific Market for Autoimmune Disorder Therapies, 2018-2024
Figure 60: Rest of World Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
Figure 61: Rest of World Market Share of Autoimmune Disorder Therapies, by Type of Immunosuppressant Drug, 2019
Figure 62: Rest of World Market Share of Autoimmune Disorder Therapies, by Indication, 2019
Figure 63: Rest of World Market Share of Autoimmune Disorder Therapies, by Country/Region, 2019
Figure 64: Brazilian Market for Autoimmune Disorder Therapies, 2018-2024
Figure 65: Gulf Cooperation Council Countries Market for Autoimmune Disorder Therapies, 2018-2024
Figure 66: South African Market for Autoimmune Disorder Therapies, 2018-2024
Figure 67: Remaining Rest of World Countries Market for Autoimmune Disorder Therapies, 2018-2024
Figure 68: Global Market Share of Autoimmune Disorder Therapies, by Manufacturer, 2019
Figure 69: AbbVie Inc.: Annual Revenue, 2016-2019
Figure 70: AbbVie Inc.: Revenue Share, by Region/Country, 2019
Figure 71: AbbVie Inc.: Revenue Share, by Business Unit, 2019
Figure 72: Amgen Inc.: Annual Revenue, 2016-2019
Figure 73: Amgen Inc.: Revenue Share, by Region/Country, 2019
Figure 74: Amgen Inc.: Revenue Share, by Products, 2019
Figure 75: AstraZeneca: Annual Revenue, 2016-2019
Figure 76: AstraZeneca: Revenue Share, by Region/Country, 2019
Figure 77: AstraZeneca: Revenue Share, by Business Unit, 2019
Figure 78: Bayer AG: Annual Revenue, 2016-2019
Figure 79: Bayer AG: Revenue Share, by Region, 2019
Figure 80: Bayer AG: Revenue Share, by Business Unit, 2019
Figure 81: Bristol-Myers Squibb: Annual Revenue, 2016-2019
Figure 82: Bristol-Myers Squibb: Revenue Share, by Region/Country, 2019
Figure 83: Bristol-Myers Squibb: Revenue Share, by Brands, 2019
Figure 84: F. Hoffmann-La Roche Ltd.: Annual Revenue, 2016-2019
Figure 85: F. Hoffmann-La Roche Ltd.: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
Figure 86: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Segment, 2019
Figure 87: Johnson & Johnson: Annual Revenue, 2016-2019
Figure 88: Johnson & Johnson: Revenue Share, by Region/Country, 2019
Figure 89: Johnson & Johnson: Revenue Share, by Business Unit, 2019
Figure 90: Mylan N.V.: Annual Revenue, 2016-2019
Figure 91: Mylan N.V.: Revenue Share, by Region, 2019
Figure 92: Mylan N.V.: Revenue Share, by Business Unit, 2019
Figure 93: Novartis AG.: Annual Revenue, 2015-2019
Figure 94: Novartis AG: Revenue Share, by Region/Country, 2019
Figure 95: Novartis AG: Revenue Share, by Business Segment, 2019
Figure 96: Pfizer Inc.: Annual Revenue, 2016-2019
Figure 97: Pfizer Inc.: Revenue Share, by Region/Country, 2019
Figure 98: Pfizer Inc.: Revenue Share, by Business Segment, 2019
Figure 99: Vertex Pharmaceuticals Inc.: Annual Revenue, 2016-2019
Figure 100: Vertex Pharmaceuticals Inc.: Research and Development Expense Annual Revenue, 2017-2019
Figure 101: Vertex Pharmaceuticals Inc.: Revenue Share, by Business Segment, 2019
Samples
LOADING...
Executive Summary
Growth of the global market is attributed to factors such as the growing prevalence of obesity, type 1 diabetes, and other chronic diseases which leads to autoimmune diseases, a strong product regulatory scenario, and strong investment in research and development activities by key market players including AstraZeneca, Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Roche), Pfizer Inc., Amgen Inc., AbbVie Inc., Novartis, Johnson and Johnson, Mylan and Bayer.
The increasing prevalence of autoimmune diseases, demand for extensive translational research for autoimmune patient treatments, the rise in technological advancements for the diagnosis of autoimmune diseases, and improved awareness about autoimmune diseases are factors expected to fuel the growth of the autoimmune disorder therapies market during the forecast period. The burden of autoimmune diseases is likely to drive the market for autoimmune disease therapeutics during the forecast period.
Companies Mentioned
- Abbvie Inc.
- Amgen Inc.
- Astrazeneca
- Bayer Ag
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Mylan N.V.
- Novartis Ag
- Pfizer Inc.
- Vertex Pharmaceuticals Inc.
